Chikara Gothong, MD
Endocrinology, Diabetes & Metabolism · Baltimore, MDNPI 1982125225
Payments from drug & device makers
Across 162 payments — averaging $23.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$858
- Dexcom, Inc.$408
- Corcept Therapeutics$308
- Tandem Diabetes Care, Inc.$267
- Lilly USA, LLC$259
- Xeris Pharmaceuticals, Inc.$222
- plus $2K from 17 others
What the payments were for
- Food & beverage$3,813100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 58 | $858 |
| Dexcom, Inc. | 7 | $408 |
| Corcept Therapeutics | 11 | $308 |
| Tandem Diabetes Care, Inc. | 4 | $267 |
| Lilly USA, LLC | 15 | $259 |
| Xeris Pharmaceuticals, Inc. | 12 | $222 |
| Sanofi-aventis U.S. LLC | 8 | $208 |
| Insulet Corporation | 8 | $191 |
| AstraZeneca | 2 | $155 |
| Amneal Pharmaceuticals LLC | 8 | $151 |
| Medtronic | 3 | $139 |
| AbbVie | 6 | $119 |
| Cequr Corporation | 2 | $103 |
| Abbott | 4 | $82 |
| Sequel Med Tech, LLC | 1 | $68 |
| Recordati_rare_diseases_inc. | 3 | $64 |
| Merck | 2 | $63 |
| Astellas Pharma US Inc | 2 | $47 |
| Amgen | 2 | $36 |
| Amryt Pharma Holdings Ltd | 1 | $24 |
| Boehringer Ingelheim | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$124
- DEXCOM G7 GSS (161)$111
- DEXCOM STELO GLUCOSE BIOSENSOR$111
- Ozempic$111
- MINIMED 770G$102
How this compares
$3,824 in reported general payments places this provider in the 65th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 640 | $789,900 |
| MounjaroTirzepatide | 274 | $369,104 |
| JardianceEmpagliflozin | 359 | $284,408 |
| TrulicityDulaglutide | 81 | $106,612 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 49 | $55,366 |
| FarxigaDapagliflozin Propanediol | 58 | $54,456 |
| Tresiba Flextouch U-200Insulin Degludec | 58 | $48,710 |
| RybelsusSemaglutide | 31 | $46,518 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $43,973 |
| Tresiba Flextouch U-100Insulin Degludec | 50 | $32,867 |
| JanuviaSitagliptin Phosphate | 31 | $29,398 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 57 | $28,824 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 23 | $26,017 |
| Cinacalcet Hcl | 28 | $24,294 |
| WegovySemaglutide | 14 | $23,298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $858 | $859,715685 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $259 | $478,341369 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $20 | $298,863374 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $208 | $55,36649 claims |
| AstraZenecaFarxiga | $155 | $54,45658 claims |
| MerckJanuvia | $63 | $29,39831 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $151 | $5,111446 claims |
| AbbVieSynthroid | $119 | $3,25550 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Baltimore
- Jean ParkBaltimore$3.7M
- Ilias SpanakisBaltimore$2.6M
- Philip LevinBaltimore$702K
- Roberto SalvatoriBaltimore$403K
- Thomas DonnerBaltimore$197K
- Adrian DobsBaltimore$190K
- Todd BrownBaltimore$143K
- Nowreen HaqBaltimore$85K
- Nanette SteinleBaltimore$74K
- Paul SackBaltimore$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.